SOCIETÀ ITALIANA
DI GERONTOLOGIA
E GERIATRIA

GLI ANZIANI:
LE RADICI DA PRESERVARE

ROMA 28 novembre 01 dicembre 2018 Auditorium della Tecnica, Roma

Simposio
"QUESTIONI APERTE NELLA GESTIONE DEL PAZIENTE ANZIANO CON FIBRILLAZIONE ATRIALE"

Il percorso decisionale e la scelta della terapia anticoagulante nell'anziano con fibrillazione atriale. Implicazioni cliniche della Valutazione Multidimensionale Geriatrica

Stefano Fumagalli, MD, PhD, FEHRA, FAIAC

Unità di Cura Intensiva Geriatrica e Unità di Aritmologia Geriatrica, Università di Firenze e AOU Careggi

Association between lifetime risk of atrial fibrillation and mortality in the oldest old

KM estimates of AF incidence between the centenarians, the nonagenarians and the octogenarians among elderly US veterans born from 1905 to 1935



Kheirbek RE,
Clin Cardiol 2018

Association between lifetime risk of atrial fibrillation and mortality in the oldest old

Proportional hazards modeling of AF as a risk factor for death among elderly US veterans stratified by medication use and Elixhauser comorbidities score



At Elixhauser Comorbidity Index Score = 0

Kheirbek RE,
Clin Cardiol 2018

Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation

Summary of documented reasons for not prescribing an OAC

	Pre-DOAC (N=86)	Post-DOAC (N=68)	p
Fall risk	42%	29%	0.154
Refusal	21%	21%	1.000
ADR (current bleeding)	16%	13%	0.765
Anemia & other hematologic disorders	6%	9%	0.54
Non-compliance, labile INR	8%	12%	0.631
Aging, dementia, psychiatric disorders, palliative care, CKD	5%	10%	0.26
Fear / high risk / history of bleeding	2%	6%	0.406

ADR: adverse drug reaction; **CKD:** chronic kidney disease

Admassie E, Am J Cardiol 2017

Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment

CHA_2DS_2-VASc score according to dependency, frailty and cognitive impairment in the ESPARTA Study (Int. Med. Dept. – N=63; 2015-6; Patients - N=837; age: 83±5 years; overall: 5.0±1.4)



Cog. Imp.: cognitive impairment

Mostaza JM,
J Geriatr Cardiol 2018

Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation

The relation between TTR and $CHADS_2$ score

(N=23425; Age: 75±10 years, $CHADS_2$ score < 2: 53.9%, 2006-2010)



Longitudinal records collected by the decision support software CoagClinic (Standing Stone, Inc., Westport, Connecticut, USA)

Nelson WW, 2013

Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry

Antithrombotic treatments at discharge/after consultation (Age; 71 (63-77) years; 250 Centres, 27 European Countries; 2013-6)



Boriani G, Europace EP 2018

Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events – ACTIVE-W
N = 2510; Age = 71± 10 years (yrs)



TTR: Time in Therapeutic Range
MMSE: Mini-Mental State Examination

Flaker GC, Circ Cardiovasc Qual Outcomes 2010

Less dementia with oral anticoagulation in atrial fibrillation

Incidence of dementia in relation to oral anticoagulant treatment (OAT) among 161896 patients with AF (propensity score matched for the likelihood of OAT; Dementia - N=26210/ 444106; Age – Dementia Yes vs. No: 81 vs. 74 years; CHA_2DS_2-VASc – Dementia Yes vs. No: 4.2 vs. 3.4)



Swedish Patient Register and the Dispensed Drug Register (2006-14)

Friberg L, Eur Heart J 2018

Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report

HRQL in patients with and without DM, by CHA_2DS_2-VASc score



DM: diabetes mellitus

Fumagalli S, Eur Heart J – Cardiovascular Pharmacotherapy 2018

Relazione tra sintomatologia depressiva e CHA_2DS_2-VASc, e punteggio alla SPPB in pazienti con FA persistente sottoposti a CVE (N=96, età: 76±8 anni)





Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation

Results of the adjusted models for traumatic intracranial bleeding events over time (the US Department of Veterans Affairs health system; N=31951, ≥75 years; age: 81±4 years)



Follow-up: 2.97 years
Incidence: 4.8 per 1000 person-years

Dodson JA,
JAMA Cardiology 2016

Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment

History of falls according to dependency, frailty and cognitive impairment in the ESPARTA Study (N=837; age: 83±5 years; overall: 25.1%)



Cog. Imp.: cognitive impairment

Mostaza JM,
J Geriatr Cardiol 2018

Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling

ENGAGE AF–TIMI 48 Analysis

Absolute Risk Reduction of HD Edoxaban Regimen Compared With Warfarin in Patients at Increased Versus Not at Increased Fall Risk



Steffel J, 2016

Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment

Polymedication (N≥5) according to dependency, frailty and cognitive impairment in the ESPARTA Study (N=837; age: 83±5 years; overall: 91.5%)



Cog. Imp.: cognitive impairment

Mostaza JM,
J Geriatr Cardiol 2018

Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke

Cumulative Incidence of Major or NMCR Bleeding According to #Medications



HR=**1.47**
(95% CI: 1.31-1.65)

HR=**1.16**
(95% CI: 1.07-1.27)

Ref.

Piccini JP, 2014

Circulation 2016

Scientific Sessions 2014

ROCKET AF

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Major bleeding among patients who used NSAIDs compared with patients who did not use NSAIDs with OAC in the RE-LY trial



Kent AP,
J Am Coll Cardiol 2018

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

All bleeding event rate of apixaban vs. warfarin by age-group



<65 – N=5471
65-74 – N=7052
≥75 – N=5678

Halvorsen S, 2014

Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation

Elaine M. Hylek, MD, MPH; Carmella Evans-Molina, MD; Carol Shea, RN;
Lori E. Henault, MPH; Susan Regan, PhD



Interruzione per ritmo sinusale (a 12 mesi) -

Età <80 anni: 63% di 91

Età ≥80 anni: 19% di 43

American Heart Association
Learn and Live

Circulation, 2007

Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report

Warfarin – N=15; Age: **79** years; CHA_2DS_2-VASc: 4.2
NAO – N=15; Age: **84** years; CHA_2DS_2-VASc: 4.4





Fumagalli S, 2014

Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation

Therapy Persistence With Dabigatran Etexilate (DE): Kaplan-Meier Curve of Time to Treatment Discontinuation Over 2 Years (the GLORIA-AF Registry, Phase II; N=2932; age: 70 years; DE discontinuation – N=828)



Paquette M, JACC 2017

Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment

Type of oral anticoagulant according to dependency, frailty and cognitive impairment in the ESPARTA Study (N=837; age: 83±5 years; men: 48.7%)



Mostaza JM,
J Geriatr Cardiol 2018

Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives

Ferguson C,
J Clin Nurs 2017

In favor of NOACs

Key barriers to anticoagulation

Treatment-related factors

1) Familiarity of burden; 2) Carelessness with adherence to treatment requirements

Socio-economic factors

1) Financial burden

Condition-related factors

1) Mental health considerations; 2) Depression and adherence; 3) End-of-life considerations

Health-system related factors

1) Multimorbidity; 2) Frailty and fear of falls; 3) Fears of bleeding

Patient-related factors

1) Cognitive dysfunction; 2) Visual impairment; 3) Patient's refusal

Social support

1) Homelessness; 2) Caregiver role; 3) Importance of routine and reminders

Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation - A Nationwide Cohort Study

Risk of ischemic stroke and ICH based on the strategies for stroke prevention

(Age: 93 years; FU 2.1±2.1 years; National Health Insurance Research Database, Taiwan)



Era without NOACs, year 1996-2011

Chao TF, Lip GYH
Circulation 2018

Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment

HAS-BLED score according to dependency, frailty and cognitive impairment in the ESPARTA Study (N=837; age: 83±5 years; overall: 2.1±0.9)



Cog. Imp.: cognitive impairment

Mostaza JM,
J Geriatr Cardiol 2018

Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment

Adherence to treatment (≥80%) according to dependency, frailty and cognitive impairment in the ESPARTA Study (N=837; age: 83±5 years; overall: 72.1%)



Cog. Imp.: cognitive impairment

Mostaza JM,
J Geriatr Cardiol 2018

Elevated Depression Symptoms Predict Long-Term Cardiovascular Mortality in Patients With Atrial Fibrillation and Heart Failure

Cardiovascular death-free survival for baseline level of depression and rhythm- vs rate-control treatment strategies



AF-CHF Trial
N = 974; **Age:** 66 years;
Men: 85.5%; **LVEF ≤35%**
Beck DI-II ≥14 = 32%

Events – N = 246 (**25.3%**)

OR = 1.57
95%CI = 1.20-2.07
P<0.001

American Heart Association
Learn and Live

Frasure-Smith N et al. Circulation 2009

From left bundle branch block to Icelandic whales: the multiple perils of atrial fibrillation management in the elderly

Valori di INR e dosi di warfarin in una paziente di 83 anni con episodi di FA parossistica in trattamento con amiodarone

(CHA_2DS_2-VASC score: 4 – ipertensione arteriosa, età, genere femminile, e HAS-BLED score: 4 – ipertensione arteriosa, INR instabile, età, uso di FANS)



Fumagalli S, 2015